Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M.

Hepatology. 2008 Feb;47(2):428-34. doi: 10.1002/hep.22065.

PMID:
18220290
2.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.

N Engl J Med. 2005 Jun 30;352(26):2682-95.

3.

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL.

Hepatology. 2010 Aug;52(2):454-61. doi: 10.1002/hep.23722.

PMID:
20683945
4.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

N Engl J Med. 2004 Sep 16;351(12):1206-17.

5.

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.

Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.

J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. doi: 10.1111/j.1440-1746.2010.06429.x.

PMID:
21332543
6.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.

Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.

PMID:
19338056
7.

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.

J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.

PMID:
24915612
8.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

Gut. 2007 May;56(5):699-705. Epub 2006 Nov 24.

9.

Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.

Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.

J Dig Dis. 2013 Aug;14(8):446-50. doi: 10.1111/1751-2980.12065.

PMID:
23615131
10.

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ, Chan HL.

Hepatology. 2010 Jun;51(6):1945-53. doi: 10.1002/hep.23568.

PMID:
20209602
11.

Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.

Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1165-9. doi: 10.1097/MEG.0b013e3283612e95.

PMID:
23571612
12.

A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.

Gish RG, Lau DT, Schmid P, Perrillo R.

Am J Gastroenterol. 2007 Dec;102(12):2718-23. Epub 2007 Jul 27.

PMID:
17662102
13.

Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.

Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, Chen J, Zhang Y, Zhang X.

J Clin Virol. 2013 Aug;57(4):318-22. doi: 10.1016/j.jcv.2013.04.003. Epub 2013 Apr 29.

PMID:
23639294
14.

Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.

Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX.

J Clin Virol. 2015 Nov;72:88-94. doi: 10.1016/j.jcv.2015.09.012. Epub 2015 Oct 9.

PMID:
26476325
15.

Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.

Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.

J Gastrointestin Liver Dis. 2009 Dec;18(4):425-31.

16.

[A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].

Huang ZL, Zhao ZX, Deng H, Zhang YF, Lu CR, Gao ZL.

Zhonghua Gan Zang Bing Za Zhi. 2010 Jun;18(6):419-22. doi: 10.3760/cma.j.issn.1007-3418.2010.06.006. Chinese.

PMID:
20587310
17.

Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.

Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T, Thongsawat S, Sanpajit T, Chonprasertsuk S, Jeamsripong W, Sripariwuth E, Komolmit P, Patcharatrakul T, Boonsirichan R, Bunchorntavakul C, Tuntipanichteerakul S, Tanwandee T; Thai Association for the Study of the Liver on Chronic Hepatitis B.

J Gastroenterol Hepatol. 2016 Nov;31(11):1874-1881. doi: 10.1111/jgh.13378.

PMID:
26997582
18.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.

J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.

PMID:
23872601
19.

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.

Ma H, Yang RF, Wei L.

J Gastroenterol Hepatol. 2010 Sep;25(9):1498-506. doi: 10.1111/j.1440-1746.2010.06282.x.

PMID:
20796146
20.

Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.

Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS.

Scand J Gastroenterol. 2012 Sep;47(8-9):1048-55. doi: 10.3109/00365521.2012.694902. Epub 2012 Jun 25.

PMID:
22726105

Supplemental Content

Support Center